These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38114758)

  • 1. Appeal for Increasing the Impact of Pharmacovigilance.
    Kant AC
    Drug Saf; 2024 Feb; 47(2):113-116. PubMed ID: 38114758
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
    Baldo P; Francescon S; Fornasier G
    Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil.
    Vogler M; Ricci Conesa H; de Araújo Ferreira K; Moreira Cruz F; Simioni Gasparotto F; Fleck K; Maciel Rebelo F; Kollross B; Silveira Gonçalves Y
    Pharmaceut Med; 2020 Oct; 34(5):327-334. PubMed ID: 32930977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance in Europe.
    Johnson CL; Hutchinson JA
    Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
    [No Abstract]   [Full Text] [Related]  

  • 5. Measuring the impact of pharmacovigilance activities, challenging but important.
    van Hunsel F; Gardarsdottir H; de Boer A; Kant A
    Br J Clin Pharmacol; 2019 Oct; 85(10):2235-2237. PubMed ID: 31368147
    [No Abstract]   [Full Text] [Related]  

  • 6. [Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system].
    Aguirre C; García M
    Med Clin (Barc); 2016 Nov; 147(10):461-464. PubMed ID: 27450163
    [No Abstract]   [Full Text] [Related]  

  • 7. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
    Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study.
    de Vries ST; Denig P; Ekhart C; Burgers JS; Kleefstra N; Mol PGM; van Puijenbroek EP
    Br J Clin Pharmacol; 2019 Jul; 85(7):1507-1515. PubMed ID: 30941789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current trends in pharmacovigilance: value and gaps of patient reporting.
    Inácio P; Cavaco A; Airaksinen M
    Int J Clin Pharm; 2018 Aug; 40(4):754-757. PubMed ID: 30006734
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on: "Pharmacovigilance in the Middle East".
    Al-Worafi YM
    Drug Saf; 2014 Aug; 37(8):651-2. PubMed ID: 24985531
    [No Abstract]   [Full Text] [Related]  

  • 12. Encouraging spontaneous reporting of adverse effects.
    Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in developing countries (part I): importance and challenges.
    Elshafie S; Zaghloul I; Roberti AM
    Int J Clin Pharm; 2018 Aug; 40(4):758-763. PubMed ID: 29248988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
    Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it possible to identify risk factors for adverse drug reactions using a pharmacovigilance database based on spontaneous reporting?
    Noguchi Y; Yoshimura T
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5737. PubMed ID: 37985422
    [No Abstract]   [Full Text] [Related]  

  • 17. Food-drug interactions risk management: An emergent piece of pharmacovigilance systems.
    Advinha AM; Fernandes JP; Perdigão M
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1245. PubMed ID: 38992909
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 19. The value of patient reporting to the pharmacovigilance system: a systematic review.
    Inácio P; Cavaco A; Airaksinen M
    Br J Clin Pharmacol; 2017 Feb; 83(2):227-246. PubMed ID: 27558545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.